NOVATO, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will hold virtual presentations

Two U.S. FDA approvals in second quarter 2020 Second quarter 2020 total revenue of $61.7 million and Crysvita revenue in Ultragenyx territories of $32.4 million Maintains full year 2020 guidance based on global COVID-19 impact to date NOVATO, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Ultragenyx

NOVATO, Calif., July 24, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on

Established UltraCare® Program Provides Ongoing Patient Support Services NOVATO, Calif., July 22, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare diseases,

Fourth U.S. FDA Approval for Ultragenyx in the Past Three Years – All for Rare Diseases which Previously Had No Approved Therapies Ultragenyx to Host Conference Call Today at 4:00 pm Eastern Time NOVATO, Calif., June 30, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a

First Approved Therapy in the United States for Patients with TIO Who Cannot Undergo Surgical Removal of Tumors TIO is Second FDA-Approved Indication for Crysvita, Which is Also Approved for the Treatment of X-linked Hypophosphatemia (XLH) NOVATO, Calif. and TOKYO, June 18, 2020 (GLOBE NEWSWIRE) --

NOVATO, Calif., May 28, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will hold virtual presentations at

NOVATO, Calif. and SAN DIEGO, May 21, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical, Inc. (Nasdaq: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases and Arcturus Therapeutics Holdings Inc.

All Patients in Cohort 3 Demonstrate Increased Time to Hypoglycemia and a Substantial Reduction in Cornstarch Use Introduction of Continuous Glucose Monitoring Reveals Early Transgene Expression and Enables More Rapid Reduction in Cornstarch Ultragenyx to Host ASGCT Recap Investor Conference Call

All three patients in Cohort 3 now confirmed responders All three complete responders in the study remain clinically and metabolically stable after longer-term follow-up Ultragenyx to host ASGCT recap investor conference call Friday, May 15 at 8:30 a.m. Eastern Time NOVATO, Calif.